Triptolide and its clinically relevant pro-drug Minnelide target high-risk MYC amplified medulloblastoma
Pre-clinical validation of the triptolide's pro-drug Minnelide for the treatment of medulloblastomas classified as group 3 and harboring MYC amplifications.